Devi L, Ohno M
Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY, USA.
Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY, USA; Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA.
Neuroscience. 2015 Oct 29;307:128-37. doi: 10.1016/j.neuroscience.2015.08.037. Epub 2015 Aug 24.
β-Site APP-cleaving enzyme 1 (BACE1) initiates the generation of amyloid-β (Aβ), thus representing a prime therapeutic target for Alzheimer's disease (AD). Previous work including ours has used BACE1 haploinsufficiency (BACE1(+/-); i.e., 50% reduction) as a therapeutic relevant model to evaluate the efficacy of partial β-secretase inhibition. However, it is unclear whether the extent of Aβ reductions in amyloid precursor protein (APP) transgenic mice with BACE1(+/-) gene ablation may vary with sex or disease progression. Here, we compared the impacts of BACE1 haploinsufficiency on Aβ concentrations and APP processing in 5XFAD Alzheimer mice (1) between males and females and (2) between different stages with moderate and robust Aβ accumulation. First, male and female 5XFAD mice at 6-7 months of age showed equivalent levels of Aβ, BACE1, full-length APP and its metabolites. BACE1 haploinsufficiency significantly lowered soluble Aβ oligomers, total Aβ42 levels and plaque burden in 5XFAD mouse brains irrespective of sex. Furthermore, there was no sex difference in reductions of β-cleavage products of APP (C99 and sAPPβ) found in BACE1(+/-)·5XFAD mice relative to BACE1(+/+)·5XFAD controls. Meanwhile, APP and sAPPα levels in BACE1(+/-)·5XFAD mice were higher than those of 5XFAD controls regardless of sex. Based on these observations, we next combined male and female data to examine the effects of BACE1 haploinsufficiency in 5XFAD mice at 12-14 months of age, as compared with those in 6-7-month-old 5XFAD mice. Oligomeric Aβ and C99 levels were dramatically elevated in older 5XFAD mice. Although the β-metabolites of APP were significantly reduced by BACE1 haploinsufficiency in both age groups, high levels of these toxic amyloidogenic fragments remained in 12-14-month-old BACE1(+/-)·5XFAD mice. The present findings are consistent with our previous behavioral data showing that BACE1 haploinsufficiency rescues memory deficits in 5XFAD mice irrespective of sex but only in the younger age group.
β-位点淀粉样前体蛋白裂解酶1(BACE1)启动β-淀粉样蛋白(Aβ)的生成,因此是阿尔茨海默病(AD)的主要治疗靶点。包括我们之前的工作在内,以往的研究使用BACE1单倍剂量不足(BACE1(+/-),即减少50%)作为治疗相关模型来评估部分β-分泌酶抑制的疗效。然而,尚不清楚BACE1(+/-)基因敲除的淀粉样前体蛋白(APP)转基因小鼠中Aβ减少的程度是否会因性别或疾病进展而有所不同。在此,我们比较了BACE1单倍剂量不足对5XFAD阿尔茨海默病小鼠(1)雄性和雌性之间以及(2)Aβ中度和大量积累的不同阶段之间Aβ浓度和APP加工的影响。首先,6至7月龄的雄性和雌性5XFAD小鼠显示出等量的Aβ、BACE1、全长APP及其代谢产物。无论性别如何,BACE1单倍剂量不足均显著降低了5XFAD小鼠脑中可溶性Aβ寡聚体、总Aβ42水平和斑块负荷。此外,相对于BACE1(+/+)·5XFAD对照,在BACE1(+/-)·5XFAD小鼠中发现的APP的β-裂解产物(C99和sAPPβ)减少没有性别差异。同时,无论性别,BACE1(+/-)·5XFAD小鼠中的APP和sAPPα水平均高于5XFAD对照。基于这些观察结果,我们接下来将雄性和雌性数据合并,以检查12至14月龄的5XFAD小鼠中BACE1单倍剂量不足的影响,并与6至7月龄的5XFAD小鼠进行比较。老年5XFAD小鼠中的寡聚体Aβ和C99水平显著升高。尽管两个年龄组中BACE1单倍剂量不足均显著降低了APP的β-代谢产物,但在12至14月龄的BACE1(+/-)·5XFAD小鼠中仍存在高水平的这些有毒淀粉样生成片段。目前的研究结果与我们之前的行为学数据一致,即BACE1单倍剂量不足可挽救5XFAD小鼠的记忆缺陷,无论性别如何,但仅在较年轻的年龄组中有效。